Of all the developing countries testing China’s COVID-19 vaccines, few are friendlier to Beijing than Pakistan. In the years leading up to the pandemic, China financed nearly $70 billion across the South Asian nation on roads, railways and power stations, and Pakistan now has two Chinese clinical trials under way, with even senior government officials being inoculated.
Yet interviews with people in Karachi, the nation’s biggest city — as well as in other developing nations from Indonesia to Brazil, together with surveys and official comments — show that China has failed to assure the millions of people who may have to rely on its vaccines.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.